Skip to main navigation Skip to search Skip to main content

Phase 2b clincial study evaluating effacacy and safety of TAR-200 in combination with cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high risk nonmuscle invasive bladder cancer (NMIBC) unresponsive to intravescial bacil

Upstate Medical University

Project: Research

Project Details

StatusActive
Effective start/end date07/28/21 → 07/27/26

Funding

  • Janssen Research and Development LLC: $149,550.00